Does the anti-ฮฑ-synuclein monoclonal antibody amlenetug slow clinical disease progression in patients with multiple system atrophy?
Does weekly extended-release exenatide 2 mg slow the rate of motor progression in people with moderate Parkinson's disease compared to placebo over 96 weeks?
Exenatide-PD3
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
The Lancet · 2025
Bottom Line: In this phase 3 trial of 194 participants with moderate Parkinson's disease, exenatide 2 mg weekly for 96 weeks was safe and well tolerated but showed no evidence of disease-modifying benefit on motor progression or any secondary outcomes compared to placebo, in contrast to earlier positive phase 2 trials.